Abstract:Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases. Observations Colorectal cancer is the third most common cause of cancer mortality for men and women in the United States, with 53 200 deaths projected in 2020. Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) Clinical trials completed in the past 5 years have demonstrated that tailoring treatment to the molecular and pathologic features of the tumor improves overall survival. Genomic profiling to detect somatic variants is important because it identifies the treatments that may be effective. For the 50% of patients with metastatic CRC with KRAS/NRAS/BRAF wild-type tumors, cetuximab and panitumumab (monoclonal antibodies to the epithelial growth factor receptor [EGFR]), in combination with chemotherapy, can extend median survival by 2 to 4 months compared with chemotherapy alone. However, for the 35% to 40% of patients with KRAS or NRAS sequence variations (formerly termed mutations), effective targeted therapies are not yet available. For the 5% to 10% with BRAF V600E sequence variations, targeted combination therapy with BRAF and EGFR inhibitors extended overall survival to 9.3 months, compared to 5.9 months for those receiving standard chemotherapy. For the 5% with microsatellite instability (the presence of numerous insertions or deletions at repetitive DNA units) or mismatch repair deficiency, immunotherapy may be used in the first or subsequent line and has improved treatment outcomes with a median overall survival of 31.4 months in previously treated patients. Conclusions and Relevance Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.

Emerging Biomarkers and Targeted Therapies Reshaping Clinical Management of Colorectal Cancer

Precision medicine and immunotherapy advances transforming colorectal cancer treatment

Advances in Epigenetic Biomarker Research in Colorectal Cancer.

Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment

State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

Translational research of new developments in targeted therapy of colorectal cancer

Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials

Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review

Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions

Advancements and Challenges in Biomarkers for Colorectal Cancer Detection: A Comprehensive Review

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Innovative Bacterial Therapies and Genetic Engineering Approaches in Colorectal Cancer: A Review of Emerging Strategies and Clinical Implications

Molecular Landscape and Therapeutic Strategies against Colorectal Cancer

Immunotherapy, Inflammation and Colorectal Cancer

Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives.

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions

New developments in targeted therapy for metastatic colorectal cancer

Colorectal cancer and therapy response: a focus on the main mechanisms involved